期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 -, 期 -, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00721-23
关键词
Aspergillus; invasive pulmonary; aspergillosis; mortality; drug therapy
Despite advancements in diagnosing and treating invasive pulmonary aspergillosis (IPA), limited knowledge of real-world treatment pathways and medication switches exists. A study on 5,410 IPA patients found that the most common initial treatments were voriconazole (49%), fluconazole (11%), and posaconazole (7%). The majority of patients remained on voriconazole (80%) or isavuconazole (78%) throughout treatment, while switches were more frequent for those initially treated with fluconazole, echinocandins, or posaconazole.
Despite advancements in diagnosing and treating invasive pulmonary aspergillosis (IPA), there is limited knowledge of real-world treatment pathways and medication switches. We queried the TrinetX global research network database and identified 5,410 patients diagnosed with IPA. The most common initial treatments were voriconazole (49%), fluconazole (11%), and posaconazole (7%). Most patients remained on voriconazole (80%) or isavuconazole (78%) throughout the treatment duration. Switches were more frequent for those initially treated with fluconazole, echinocandins, or posaconazole.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据